Seaport Therapeutics announces clinical trial update, using Monash invention

Professor Christopher Porter (far right) and his team at Monash University developed the Glyph platform used by Seaport Therapeutics.

18 July 2025

The clinical-stage biopharmaceutical company, Seaport Therapeutics, which uses a unique drug delivery platform based on a Monash University invention, has announced that the first patient has been dosed in a Phase 2b study (BUOY-1) of GlyphAlloTM (SPT-300 or Glyph Allopregnanolone) in major depressive disorder, with or without anxious distress.

SPT-300 is an oral form of the drug allopregnanolone. Glyph is Seaport’s proprietary prodrug technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs, including SPT-300.

The Glyph platform was initially developed by Professor Chris Porter and his team at the Monash Institute of Pharmaceutical Sciences. Since the licence of the Monash technology was initiated to Seaport’s co-founder PureTech Health in 2017, and now exclusively licenced to Seaport, Professor Porter and the MIPS team have worked closely with both PureTech and Seaport to progress the platform and advance the development of drug candidates including SPT-300 (formerly known as LYT-300) and other drugs in Seaport’s pipeline.

To learn more, visit Seaport Therapeutics for the original press release: https://seaporttx.com/press-release/seaport-therapeutics-announces-first-patient-dosed-in-phase-2b-buoy-1-study-of-glyphallotm-spt-300-in-major-depressive-disorder-mdd-with-or-without-anxious-distress/